Fig. 3
Top 20 high-risk signals for pembrolizumab monotherapy (A) and its combination with lenvatinib (B) presented by a forest plot.
Fig. 3 | Scientific Reports
Top 20 high-risk signals for pembrolizumab monotherapy (A) and its combination with lenvatinib (B) presented by a forest plot.
